CLL1-CD33 CAR-T cells for relapsed or refractory acute myeloid leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new type of immune cell therapy (CAR-T) designed to find and kill leukemia cells that carry two specific markers (CLL-1 and CD33). It is for adults with acute myeloid leukemia that has come back or is not responding to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have acute myeloid leukemia that has returned or is not improving after standard treatment.
- Your leukemia cells must test positive for both CLL-1 and CD33 markers (a lab test will check this).
- You must be well enough to carry out daily activities (ECOG score 0-2).
- You must not have had CAR-T cell therapy or any other gene-modified cell therapy before.
- You must not have serious organ problems (kidney, liver, heart) or active uncontrolled infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment made from your own immune cells (CAR-T cells) that are designed to find and kill leukemia cells that have the FLT3 protein. It is for people with acute myeloid leukemia (AML) that has not responded to standard therapy or has returned after treatment.
This trial tests a new type of immune cell therapy (CAR-T) that targets three proteins (CLL1, CD33, NKG2D) on leukemia cells in patients with acute myeloid leukemia that has not responded to or come back after prior treatment.
This trial tests a new type of immune cell therapy (called CAR-T) designed to target and fight acute myeloid leukemia (AML) that has come back or didn't respond to standard treatments. The therapy uses your own immune cells, modified in the lab to recognize and kill leukemia cells.
This trial tests a new treatment called CAR-T cell therapy for people with certain types of blood cancer that have come back or not responded to standard treatments. CAR-T cells are specially designed to find and destroy cancer cells. The goal is to see if this therapy is safe and works for patients whose cancer cells have specific markers (CD33, CD123, or CLL-1).
This trial tests a personalized cell therapy called CD33 CAR-T for people whose acute myeloid leukemia has come back or isn't responding to standard treatments. The goal is to see if it's safe and can help eliminate leukemia cells that carry the CD33 protein.
This trial tests a new type of immune therapy called CAR T cells that target the CD33 protein on leukemia cells. It is for people with AML that has returned or not gone away after standard treatments, and who have a stem cell donor available for a transplant afterward.
Hear when a new Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.